Prahallad et al., have demonstrated increased activity by combined treatment of the EGFR inhibitor cetuximab with vemurafenib by linking ERK and AKT signaling through the intermediary CDC25C in BRAF mutated colon cancer cells [15]. The gene discussed is EGFR; the disease is colonic neoplasm.